Cargando…

Comparative Analysis of PSA Density and an MRI-Based Predictive Model to Improve the Selection of Candidates for Prostate Biopsy

SIMPLE SUMMARY: Magnetic resonance imaging (MRI)-associated prostate-specific antigen density (mPSAD) and MRI predictive models have been proposed for improving the selection of candidates for prostate biopsy among men with suspected prostate cancer (PCa). While the calculation of mPSAD only require...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morote, Juan, Borque-Fernando, Angel, Triquell, Marina, Celma, Anna, Regis, Lucas, Mast, Richard, de Torres, Inés M., Semidey, María E., Abascal, José M., Servian, Pol, Santamaría, Anna, Planas, Jacques, Esteban, Luis M., Trilla, Enrique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139805/ https://www.ncbi.nlm.nih.gov/pubmed/35625978 http://dx.doi.org/10.3390/cancers14102374

Ejemplares similares

Comparison of Proclarix, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRI
por: Campistol, Miriam, et al.
Publicado: (2022)

The Barcelona Predictive Model of Clinically Significant Prostate Cancer
por: Morote, Juan, et al.
Publicado: (2022)

A Clinically Significant Prostate Cancer Predictive Model Using Digital Rectal Examination Prostate Volume Category to Stratify Initial Prostate Cancer Suspicion and Reduce Magnetic Resonance Imaging Demand
por: Morote, Juan, et al.
Publicado: (2022)

Multiparametric Magnetic Resonance Imaging Grades the Aggressiveness of Prostate Cancer
por: Morote, Juan, et al.
Publicado: (2022)

The Efficacy of Proclarix to Select Appropriate Candidates for Magnetic Resonance Imaging and Derived Prostate Biopsies in Men with Suspected Prostate Cancer
por: Morote, Juan, et al.
Publicado: (2022)

Improving the Early Detection of Clinically Significant Prostate Cancer in Men in the Challenging Prostate Imaging-Reporting and Data System 3 Category
por: Morote, Juan, et al.
Publicado: (2022)

Comparison of Rotterdam and Barcelona Magnetic Resonance Imaging Risk Calculators for Predicting Clinically Significant Prostate Cancer
por: Morote, Juan, et al.
Publicado: (2023)

The True Utility of Predictive Models Based on Magnetic Resonance Imaging in Selecting Candidates for Prostate Biopsy
por: Morote, Juan, et al.
Publicado: (2022)

A risk‐organised model for clinically significant prostate cancer early detection
por: Morote, Juan, et al.
Publicado: (2023)

Stratifying the initial prostate cancer suspicion to avoid magnetic resonance exams by sequencing men according to serum prostate‐specific antigen, digital rectal examination and the prostate‐specific antigen density based on digital rectal prostate volume category
por: Morote, Juan, et al.
Publicado: (2022)

Magnetic Resonance Imaging-Based Predictive Models for Clinically Significant Prostate Cancer: A Systematic Review
por: Triquell, Marina, et al.
Publicado: (2022)

Application of One-Step Nucleic Acid Amplification (OSNA) in different cancer entities and usefulness in prostate cancer: a systematic review
por: Cuadras, Mercè, et al.
Publicado: (2022)

Multiparametric MRI for Staging of Prostate Cancer: A Multicentric Analysis of Predictive Factors to Improve Identification of Extracapsular Extension before Radical Prostatectomy
por: Triquell, Marina, et al.
Publicado: (2022)

Serum Luteinizing Hormone Testing Can Identify Optimal Medical Castration
por: Morote, Juan, et al.
Publicado: (2020)

A Diagnostic Accuracy Study of Targeted and Systematic Biopsies to Detect Clinically Significant Prostate Cancer, including a Model for the Partial Omission of Systematic Biopsies
por: Morote, Juan, et al.
Publicado: (2023)

Accuracy of serum luteinizing hormone and serum testosterone measurements to assess the efficacy of medical castration in prostate cancer patients
por: Morote, Juan, et al.
Publicado: (2017)

Definition of Castrate Resistant Prostate Cancer: New Insights
por: Morote, Juan, et al.
Publicado: (2022)

Methods for Evaluating the Efficacy of Medical Castration: A Systematic Review
por: Aguilar, Adriana, et al.
Publicado: (2023)

Role of Serum Cholesterol and Statin Use in the Risk of Prostate Cancer Detection and Tumor Aggressiveness
por: Morote, Juan, et al.
Publicado: (2014)

Bladder Cancer in an Inguinoscrotal Vesical Hernia
por: Regis, Lucas, et al.
Publicado: (2012)

A Systematic Review of the Current Status of Magnetic Resonance–Ultrasound Images Fusion Software Platforms for Transperineal Prostate Biopsies
por: Paesano, Nahuel, et al.
Publicado: (2023)

The Relationship between Prostate Biopsy Results and PSA and Free PSA Ratio Changes in Elevated Serum PSA Patients with and without Antibiotherapy
por: Duran, Mesut Berkan, et al.
Publicado: (2020)

Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance
por: Kotb, A F, et al.
Publicado: (2011)

Nuclear and cytosolic pS727-STAT3 levels correlate with overall survival of patients affected by clear cell renal cell carcinoma (ccRCC)
por: Arévalo, Jazmine, et al.
Publicado: (2021)

Optimal PSA Threshold for Obtaining MRI-Fusion Biopsy in Biopsy-Naïve Patients
por: Wang, Luke L., et al.
Publicado: (2021)

Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy?
por: Azab, Sherif, et al.
Publicado: (2012)

Simultaneous Treatment with Statins and Aspirin Reduces the Risk of Prostate Cancer Detection and Tumorigenic Properties in Prostate Cancer Cell Lines
por: Olivan, M., et al.
Publicado: (2015)

Pre-biopsy MRI as an adjunct for cancer detection in men with elevated PSA and no previous biopsy
por: Uriburu-Pizarro, Facundo, et al.
Publicado: (2017)

A Comparative Performance Analysis of Total PSA, Percentage Free PSA, PSA Velocity, and PSA Density versus the Detection of Primary Circulating Prostate Cells in Predicting Initial Prostate Biopsy Findings in Chilean Men
por: Murray, Nigel P., et al.
Publicado: (2014)

Prostate biopsy for elevated prostate specific antigen (PSA) – Indian perspective
por: Ragavan, N.
Publicado: (2014)

Multidisciplinary Consensus on the Prevention and Treatment of Osteoporosis and Fragility Fractures in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy
por: Casado, Enrique, et al.
Publicado: (2022)

Prostate-specific antigen kinetics contributes to decision making for biopsy referral: the predictive implication for PSA retest in patients with elevated PSA levels
por: Kobayashi, Minoru, et al.
Publicado: (2023)

Validating fPSA Glycoprofile as a Prostate Cancer Biomarker to Avoid Unnecessary Biopsies and Re-Biopsies
por: Bertok, Tomas, et al.
Publicado: (2020)

Temperature Control of psaA Expression by PsaE and PsaF in Yersinia pestis
por: Quinn, Joshua D., et al.
Publicado: (2019)

A New Interpretation of the Standard PSA-Test
por: Esteban, Ernesto P, et al.
Publicado: (2020)

Association among the R.E.N.A.L. nephrometry score and clinical outcomes in patients with small renal masses treated with percutaneous contrast enhanced ultrasound radiofrequency ablation
por: Konstantinidis, Cristian, et al.
Publicado: (2019)

The comparative effectiveness of mpMRI and MRI-guided biopsy vs regular biopsy in a population-based PSA testing: a modeling study
por: Getaneh, Abraham M., et al.
Publicado: (2021)

The Chances of Subsequent Cancer Detection in Patients with a PSA > 20 ng/ml and an Initial Negative Biopsy
por: Shaida, Nadeem, et al.
Publicado: (2009)

Raising cut-off value of prostate specific antigen (PSA) for biopsy in symptomatic men in India to reduce unnecessary biopsy
por: Agnihotri, Shalini, et al.
Publicado: (2014)

Assessment of PSA-Age volume score in predicting positive prostate biopsy findings in Turkey
por: Uçer, Oktay, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_0nuh640fclecmldtvlcn8odnvp